Key result
A newly developed LC-MS/MS method confirmed that the test formulation of 25 mg cinnarizine had a relative bioavailability of 101.83% compared to the reference product, establishing bioequivalence.
Why the study?
Does a generic cinnarizine 25 mg tablet have comparable bioavailability to the reference product in healthy volunteers?
RCT (n=24)
Open-label
Randomized
No
Does a generic cinnarizine 25 mg tablet have comparable bioavailability to the reference product in healthy volunteers?
Effect estimate: 101.83% relative bioavailability
Absolute Event Rate: 493.078% vs 484.234%
A newly developed LC-MS/MS method successfully demonstrated bioequivalence between a generic cinnarizine 25 mg tablet and the reference product in healthy Indian volunteers.
Supports generic cinnarizine substitution in practice; confirms the LC-MS/MS method for future bioequivalence trials.
Antihistamine is drug which antagonises the action of histamine at the H1 receptors. Qualitatively all H1 antihistaminic have similar actions, but there are quantitative differences, especially in the sedative property. These drugs effectively block the histamine induced bronchoconstriction, contraction of intestinal and smooth muscle and triple response. It also suppressed the immediate or type-I hypersensitivity reaction but certain drugs are effective in preventing motion sickness. Cinnarizine is one of the drugs of antihistaminic medication. It is used to treat problems associated with the inner ear and the brain. The medicine is used to treat dizziness and sickness associated with motion sickness. This drug used in the treatment of vertigo and vestibular disorder and heart and blood vessel disorder. Cinnarizine inhibits the contractions of vascular smooth muscle cells by blocking L-type and T-type voltage gated calcium channel and it also binding to dopamine D2 receptor, histamine H1 receptor and muscarinic acetylcholine receptor. Cinnarizine contain diphenylmethylpiperazine group which protonated precursor ion was 369.3 and product ion 167.2 by using 0.1% formic acid in acetonitrile with 0.1% formic acid containing milli Q water added with 10.mM ammonium acetate as a binary flow. Internal standard precursor ion was 268.2 and product ion was 116.1 as a positive mode. The run time was very short 3.5 min and in between this run time 90% aqueous phase flow upto 0.9 min and 10% upto 2.50 min then again 90% flow upto 3.5 min. This method showed very low matrix effect which calculated matrix factor was 0.87 to 0.94 and recovery was very high 86.88% to 99.57%. So this method was very specific, selective, sensitive and reproducible which used for quantification of cinnarizine concentration of unknown Indian healthy human volunteers from their plasma.
No takes yet. Share an insight, caveat, or question.
Pal et al. (2018) conducted an RCT in Healthy volunteers (n=24). Cinnarizine (Test formulation) vs. Cinnarizine (Reference formulation, Stugeron) was evaluated on Relative Bioavailability (based on AUC0-t) (101.83% relative bioavailability). A newly developed LC-MS/MS method confirmed that the test formulation of 25 mg cinnarizine had a relative bioavailability of 101.83% compared to the reference product, establishing bioequivalence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: